DNA Methylation Inhibitors in Cancer Therapy: The Immunity Dimension

Jonathan D. Licht

doi:10.1016/j.cell.2015.08.005

DNA Methylation Inhibitors in Cancer Therapy: The Immunity Dimension

Jonathan D. Licht

Research output: Contribution to journal › Short survey › peer-review

46 Scopus citations

Abstract

DNA demethylating agents are approved for some blood malignancies and are under active investigation in solid tumors, but how these drugs work has remained unclear. In this issue of Cell, two groups show that these agents activate a toxic cellular antiviral program through transcriptional activation of endogenous retroviral sequences.

Original language	English
Pages (from-to)	938-939
Number of pages	2
Journal	Cell
Volume	162
Issue number	5
DOIs	https://doi.org/10.1016/j.cell.2015.08.005
State	Published - 27 Aug 2015
Externally published	Yes

Access to Document

10.1016/j.cell.2015.08.005

Cite this

@article{3211f97ace4e446a85408b3508cf3a0b,

title = "DNA Methylation Inhibitors in Cancer Therapy: The Immunity Dimension",

abstract = "DNA demethylating agents are approved for some blood malignancies and are under active investigation in solid tumors, but how these drugs work has remained unclear. In this issue of Cell, two groups show that these agents activate a toxic cellular antiviral program through transcriptional activation of endogenous retroviral sequences.",

author = "Licht, {Jonathan D.}",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2015",

month = aug,

day = "27",

doi = "10.1016/j.cell.2015.08.005",

language = "English",

volume = "162",

pages = "938--939",

journal = "Cell",

issn = "0092-8674",

publisher = "Cell Press",

number = "5",

}

TY - JOUR

T1 - DNA Methylation Inhibitors in Cancer Therapy

T2 - The Immunity Dimension

AU - Licht, Jonathan D.

PY - 2015/8/27

Y1 - 2015/8/27

N2 - DNA demethylating agents are approved for some blood malignancies and are under active investigation in solid tumors, but how these drugs work has remained unclear. In this issue of Cell, two groups show that these agents activate a toxic cellular antiviral program through transcriptional activation of endogenous retroviral sequences.

AB - DNA demethylating agents are approved for some blood malignancies and are under active investigation in solid tumors, but how these drugs work has remained unclear. In this issue of Cell, two groups show that these agents activate a toxic cellular antiviral program through transcriptional activation of endogenous retroviral sequences.

UR - http://www.scopus.com/inward/record.url?scp=84940392888&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2015.08.005

DO - 10.1016/j.cell.2015.08.005

M3 - Short survey

C2 - 26317460

AN - SCOPUS:84940392888

VL - 162

SP - 938

EP - 939

JO - Cell

JF - Cell

SN - 0092-8674

IS - 5

ER -

DNA Methylation Inhibitors in Cancer Therapy: The Immunity Dimension

Abstract

Access to Document

Fingerprint

Cite this